Abstract
Exploiting the potential of natural compounds to attenuate endogenous redox status to achieve neuroprotection is a novel concept in human disease therapy. This has necessitated a need to identify newer efficient phytochemicals possessing propensity to act on various biochemical therapeutic targets with low or no toxicity. Selaginella is a lithophytic pteridophyte which grows on constantly irrigated rocks in high altitude zones in different parts of the world. It is appraised to be “Sanjeevani” (the resurrection herb) based on its mythological reference in the Indian epic “Ramayana”. Due to the presence of a unique disaccharide, trehalose, most species of Selaginella can survive severe drought conditions, maintaining the plant’s structural stability and resurrect during rains. Several species of the genus are used in ethnic medicine for the therapy of jaundice, chronic trachitis, lung cancer, labor pain and wound healing. The major natural compounds in the genus Selaginella are characteristic flavonoid-dimers, called ‘biflavonoids’. Although various biological effects of Selaginella have been documented in vitro, studies on its neuromodulatory properties are nonexisting despite the presence of potentially therapeutic biflavonoids. We have reviewed the existing literature on the possible pharmacological properties of Selaginella. Further, recent evidence gathered from our laboratory on the neuromodulatory propensity of S. delicatula employing in vivo models of chemically induced neurodegenerative diseases in rodents and Drosophila are discussed. Our findings point to a mechanism which modulates redox status and mitochondrial dysfunction suggesting their possible therapeutic use in oxidative stress-mediated neurodegenerative diseases including Parkinson's disease.
Keywords: Biflavonoids, Neuroprotection, Pteridophyte, Sanjeevani, Selaginella, S. delicatula.
CNS & Neurological Disorders - Drug Targets
Title:Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
Volume: 13 Issue: 1
Author(s): Girish Chandran and Muralidhara
Affiliation:
Keywords: Biflavonoids, Neuroprotection, Pteridophyte, Sanjeevani, Selaginella, S. delicatula.
Abstract: Exploiting the potential of natural compounds to attenuate endogenous redox status to achieve neuroprotection is a novel concept in human disease therapy. This has necessitated a need to identify newer efficient phytochemicals possessing propensity to act on various biochemical therapeutic targets with low or no toxicity. Selaginella is a lithophytic pteridophyte which grows on constantly irrigated rocks in high altitude zones in different parts of the world. It is appraised to be “Sanjeevani” (the resurrection herb) based on its mythological reference in the Indian epic “Ramayana”. Due to the presence of a unique disaccharide, trehalose, most species of Selaginella can survive severe drought conditions, maintaining the plant’s structural stability and resurrect during rains. Several species of the genus are used in ethnic medicine for the therapy of jaundice, chronic trachitis, lung cancer, labor pain and wound healing. The major natural compounds in the genus Selaginella are characteristic flavonoid-dimers, called ‘biflavonoids’. Although various biological effects of Selaginella have been documented in vitro, studies on its neuromodulatory properties are nonexisting despite the presence of potentially therapeutic biflavonoids. We have reviewed the existing literature on the possible pharmacological properties of Selaginella. Further, recent evidence gathered from our laboratory on the neuromodulatory propensity of S. delicatula employing in vivo models of chemically induced neurodegenerative diseases in rodents and Drosophila are discussed. Our findings point to a mechanism which modulates redox status and mitochondrial dysfunction suggesting their possible therapeutic use in oxidative stress-mediated neurodegenerative diseases including Parkinson's disease.
Export Options
About this article
Cite this article as:
Chandran Girish and Muralidhara , Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications, CNS & Neurological Disorders - Drug Targets 2014; 13 (1) . https://dx.doi.org/10.2174/18715273113126660188
DOI https://dx.doi.org/10.2174/18715273113126660188 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Applications of Lentiviral Vectors for shRNA Delivery and Transgenesis
Current Gene Therapy EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo
Current Cancer Drug Targets Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science Nanomedicine to Overcome Cancer Multidrug Resistance
Current Drug Metabolism MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Genetic Modification of Natural Killer Cells for Leukemia Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design Ionotropic Glutamate Receptors & CNS Disorders
CNS & Neurological Disorders - Drug Targets Magnetic Field-Assisted Gene Delivery: Achievements and Therapeutic Potential
Current Gene Therapy Combination Therapy of Intraperitoneal Rapamycin and Convection- Enhanced Delivery of Nanoliposomal CPT-11 in Rodent Orthotopic Brain Tumor Xenografts
Current Cancer Drug Targets Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach
Anti-Cancer Agents in Medicinal Chemistry Rho GTPase Activating Proteins in Cancer Phenotypes
Current Protein & Peptide Science Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Arsenic Trioxide-based Nanomedicines as a Therapeutic Combination Approach for Treating Gliomas: A Review
Current Nanoscience Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Current Pharmaceutical Design Isoflavones, their Glycosides and Glycoconjugates. Synthesis and Biological Activity
Current Organic Chemistry Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design